Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 16/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29636525 | 0.98 | KISS1R (0.53) | KISS1RGHSRIL23R | |
| SCHEMBL31406265 | 0.95 | ERAP2 (0.54) | KISS1RERAP2GHSR | |
| SCHEMBL30947673 | 0.94 | ERAP2 (0.57) | KISS1RERAP2 | |
| SCHEMBL30919237 | 0.93 | KISS1R (0.54) | KISS1RERAP2GHSR | |
| SCHEMBL31614911 | 0.93 | KISS1R (0.55) | KISS1RERAP2GHSRIL23R | |
| SCHEMBL29637604 | 0.93 | KISS1R (0.54) | KISS1R | |
| SCHEMBL29672123 | 0.93 | KISS1R (0.55) | KISS1RGHSRIL23R | |
| SCHEMBL29672131 | 0.92 | NPY1R (0.56) | KISS1RGHSR | |
| SCHEMBL30903443 | 0.92 | KISS1R (0.58) | KISS1R | |
| SCHEMBL30641907 | 0.92 | NPY1R (0.50) | KISS1RERAP2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | claimed |
| EP-4554607-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-05-21 | — | — | EP | claimed |
| EP-3356386-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS INC (US) | 2024-02-14 | — | — | EP | claimed |
| WO-2024015880-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20220226425-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS INC (US) | 2022-07-21 | — | — | US | claimed |
| US-20250186536-A1 | SUSTAINED RELEASE PEPTIDE FORMULATIONS | RHYTHM PHARMACEUTICALS INC (US) | 2025-06-12 | — | — | US | disclosed |
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. | 2024-02-22 | — | — | US | disclosed |
| EP-3356386-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS INC (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4216979-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116507353-A | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-108431023-B | Methods of treating melanocortin-4 receptor pathway-related disorders | 节奏制药公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240058414-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | KISS1R 545/4885ERAP2 698/4885GHSR 29/4885 |
| US-20220226425-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | KISS1R 380/4885ERAP2 634/4885GHSR 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.